OMEICOS
OMEICOS Therapeutics is developing a novell molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation.
OMEICOS has raised €17M across 1 funding round from 3 investors, most recently a Series C round in Oct 2018. Based in Berlin, Germany; founded 2013; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€17M
€17,000,000
Funding rounds
1
Investors
3
distinct backers
Active since
2018-10
latest 2018-10
Funding by year
EUR raised per yearOMEICOS — funding by year — interactive chart.
Data table
| OMEICOS — funding by year | |
|---|---|
| 2018 | €17M |
Signals
High confidenceRaise-next likelihood9
base rate 50% for Series C
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2018-10-01 | Series C | €17M | Forbion,SICAR,Vesalius Biocapital Partners | View deal → |
Investors
3Related news
Similar companies
same sector or country- Delivery Hero€7.1BGermany · E-commerce
- Enpal€4.6BGermany · Cleantech
- Auxmoney€3.5BGermany · Fintech
- Helsing€2.9BGermany · AI
- Philips€2.6BNetherlands · Healthtech
- Isomorphic Labs€2.3BUK · Healthtech
Global coverage: FundingData